Biomerica announces findings from clinical trial on IBS

Biomerica (BMRA) announced that patients with Irritable Bowel Syndrome, or IBS, may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods IBS blood test. The findings from a clinical trial published in Gastroenterology, demonstrate that participants who adhered to a personalized diet therapy based on the test results experienced greater symptom improvement compared to those following a sham elimination diet. The inFoods IBS test was designed specifically for IBS patients. It identifies individual foods that trigger an elevated Immunoglobulin G , or IgG, antibody responses-which is a marker of inflammation associated with IBS symptoms. Every food in the inFoods IBS panel is set with a 95% confidence interval cutoff to provide accurate results. No other IBS product has this technology. The randomized, multicenter, double-blind, placebo-controlled trial enrolled 238 IBS patients across eight leading academic centers in the U.S. Each participant was tested for IgG antibody responses to 18 common IBS trigger foods using the inFoods IBS product.